Clinical evaluation of smartphone-based fluorescence imaging for guidance and monitoring of ALA PDT

Abstract

India has one of the highest rates of oral cancer incidence in the world, with an estimated 80,000 new cases per year, accounting for 30% of reported cancers. In rural areas, a lack of adequate medical infrastructure contributes to unchecked disease progression and dismal mortality rates. PDT emerges as a potential modality which can be implemented in resource limited settings, while photosensitizer fluorescence can be leveraged for treatment guidance. Here, as part of an ongoing clinical study evaluating low-cost technology for ALA PDT treatment, we evaluated the capability of a simple smartphone-based device for imaging ALA-induced PpIX fluorescence for treatment guidance and monitoring. The imaging device itself consists of an annulus of 405nm LEDs for PpIX excitation with emission filter in the center mounted over the phone camera. 21 subjects having <2 cm diameter (mean size; ∼ 1.29 cm 2) lesions with micro-invasive (≤ 5mm. depth) moderately/well-differentiated squamous cell carcinoma were administered 60 mg/kg ALA in oral solution and imaged before and after delivery of 100 J/cm 2 total light dose to the lesion surface. We will present comparative analysis of pre-and post-treatment fluorescence, white light (WL), and ultrasound images. In general, PpIX fluorescence images obtained prior to therapeutic light delivery are able to resolve lesion margins while dramatic photobleaching in post-treatment images confirms the irradiated zone. Overall this approach is able to generate sufficient fluorescence contrast for treatment guidance and monitoring photobleaching while the use of a smartphone-based device provides a low-cost, widely available platform with potential for telemedicine integration.

Clinical evaluation of smartphone-based fluorescence imaging for guidance and monitoring of ALA-PDT treatment of early oral cancer

“…8 The wide availability and popularity of smartphones, particularly in the developing countries, make this device promising as a low-cost, portable, and capable theragnostic cancer technology for global health. [9][10][11] Building on previous preliminary findings, 12 we report here an evaluation of this simple and low-cost fluorescence imaging approach for guidance and monitoring of PDT treatment in the clinic.…”